Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Neuphoria Therapeutics Inc. (NEUP) had Stock-Based Compensation of $0.16M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$-0.01M |
|
$-8.88M |
|
-- |
|
$-0.01M |
|
$5.82M |
|
$-5.83M |
|
$-3.32M |
|
$-9.15M |
|
$-9.15M |
|
$-8.88M |
|
$-8.88M |
|
$-8.88M |
|
$-8.88M |
|
$-5.83M |
|
$-5.67M |
|
1.62M |
|
1.62M |
|
$-5.55 |
|
$-5.55 |
|
| Balance Sheet Financials | |
$15.04M |
|
$0.00M |
|
$13.55M |
|
$28.59M |
|
$4.22M |
|
-- |
|
$5.37M |
|
$9.59M |
|
$19.00M |
|
$5.56M |
|
$19.00M |
|
1.98M |
|
| Cash Flow Statement Financials | |
$0.08M |
|
-- |
|
$1.53M |
|
$12.69M |
|
$14.29M |
|
$1.60M |
|
|
Stock-Based Compensation |
$0.16M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
43982.90% |
|
43982.90% |
|
-- |
|
68972.03% |
|
66962.46% |
|
$0.08M |
|
-- |
|
-- |
|
-- |
|
-0.00 |
|
-- |
|
-1.11 |
|
-81.05 |
|
-46.75% |
|
-159.80% |
|
-31.07% |
|
-46.75% |
|
$9.61 |
|
$0.05 |
|
$0.05 |
|